(NASDAQ:STAA) LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, issued the following statement: “The merger with Alcon provides STAAR stockholders with compelling, premium cash value, including a 51% premium to the closing price of STAAR common stock on August 4, 2025 (the day prior to the agreement being announced) and a 59% premium to STAAR’s 90-day Volume Weight
Related Questions
How will the announced premium and cash consideration affect STAAR's share price and trading volume in the short term?
What are the expected synergies and integration timeline between STAAR Surgical and Alcon, and how might they impact future earnings?
What regulatory approvals and potential antitrust challenges could affect the completion of the merger and its timing?